Document:

EX-10.6

 Exhibit 10.6 

REGISTRATION RIGHTS AGREEMENT 

THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), is made as of the 30th day of November, 2020, by and among LumiraDx
Limited, an exempted company with limited liability incorporated in the Cayman Islands (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an
“Investor”. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Subscription Letter (as defined below). 

RECITALS 

WHEREAS, the Company and the Investors are parties to certain subscription letters in respect of Preferred Shares between the Company
and each of the Investors (the “Subscription Letters”), in each case dated on or around the date of this Agreement; and 

WHEREAS, in order to induce the Company to enter into the Subscription Letters and to induce the Investors to invest funds in the
Company pursuant to the Subscription Letters, the Investors and the Company hereby agree that this Agreement shall govern the rights of the Investors to cause the Company to register the Common Shares of the Company underlying the Preferred Shares
to be issued pursuant to the Subscription Letters (“Common Shares”), in each case of US$0.001 each in the share capital of the Company, and shall govern certain other matters as set forth in this Agreement; 

NOW, THEREFORE, the parties hereby agree as follows: 

1.    Definitions. For purposes of this Agreement: 

1.1    “Affiliate” means, with respect to any specified Person, any other Person who, directly or
indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer, director or trustee of such Person, or any venture capital fund or registered investment
company now or hereafter existing that is controlled by one or more general partners, managing members or investment adviser of, or shares the same management company or investment adviser with, such Person. 

1.2    “Articles of Association” means the Company’s Articles of Association, as amended and/or
restated from time to time. 
 1.3    “Board of Directors” means the board of directors of the Company.

 1.4    “Common Shares” shall have the meaning set forth in the Recitals. 

1.5    “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto
may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or
alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii)

 
an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged
violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state
securities law. 
 1.6    “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the
rules and regulations promulgated thereunder. 
 1.7    “Excluded Registration” means (i) a
registration relating to the sale or grant of securities to employees or consultants of the Company or a subsidiary pursuant to a share option, share purchase, equity incentive or similar plan; (ii) a registration relating to an SEC Rule 145
transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration
in which the only Common Shares being registered are Common Shares issuable upon conversion of debt securities that are also being registered. 

1.8    “Form S-1” means such form under the Securities Act
as in effect on the date hereof (or the foreign private issuer equivalent Form F-1) or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.9    “Form S-3” means such form under the Securities Act
as in effect on the date hereof (or the foreign private issuer equivalent Form F-3) or any registration form under the Securities Act subsequently adopted by the SEC that permits forward incorporation of
substantial information by reference to other documents filed by the Company with the SEC. 

1.10    “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

1.11    “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent,
spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law,
or sister-in-law, including, adoptive relationships, of a natural person referred to herein. 

1.12    “Initiating Holders” means, collectively, Holders who properly initiate a registration request
under this Agreement. 
 1.13    “IPO” means the Company’s first underwritten public offering of
its Common Shares under the Securities Act. 
 1.14    “Person” means any individual, corporation,
partnership, trust, limited liability company, association or other entity. 
 1.15    “Preferred
Shares” or “Series B Preferred Shares” means the Company’s Series B 8% Cumulative Convertible Preferred Shares of US$0.001 each in the share capital of the Company. 

  
 2 

 1.16    “Registrable Securities” means (i) the
Common Shares issuable or issued upon conversion of the Preferred Shares; (ii) any Common Shares, or any Common Shares issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company,
acquired by the Investors after the date hereof; and (iii) any Common Shares issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or
in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under
this Agreement are not assigned pursuant to Subsection 3.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement. 

1.17    “Registrable Securities then outstanding” means the number of shares determined by adding the
number of outstanding Common Shares that are Registrable Securities and the number of Common Shares issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. 

1.18    “Restricted Securities” means the securities of the Company required to be notated with the
legend set forth in Subsection 2.12(b) hereof. 
 1.19    “SEC” means the Securities and
Exchange Commission. 
 1.20    “SEC Rule 144” means Rule 144 promulgated by the SEC under the
Securities Act. 
 1.21    “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities
Act. 
 1.22    “Securities Act” means the Securities Act of 1933, as amended, and the rules and
regulations promulgated thereunder. 
 1.23    “Selling Expenses” means all underwriting discounts,
selling commissions, and share transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company
as provided in Subsection 2.6. 
 2.    Registration Rights. The Company covenants and agrees as follows:

 2.1    Demand Registration. 

(a)    Form S-1 Demand. If at any time after the earlier of (i) 5 years
after the date of this Agreement or (ii) 180 days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of a majority of the Registrable Securities then outstanding that the Company file a
Form S-1 registration statement with respect to a majority of the Registrable Securities then outstanding (or a lesser percent if the anticipated aggregate offering price, net of Selling Expenses, would
exceed $15 million), then the Company shall (x) within 10 days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as

  
 3 

 
practicable, and in any event within 60 days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under
the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice
given by each such Holder to the Company within 20 days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

(b)    Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least 25% of the Registrable Securities then outstanding that the Company file a Form S-3
registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $3 million, then the Company shall (i) within 10 days after the
date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within 45 days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the
Company within 20 days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

(c)    Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant
to this Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board of Directors it would be materially detrimental to the Company and its shareholders for such
registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition,
corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the
Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall
be tolled correspondingly, for a period of not more than 90 days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any twelve (12) month period;
and provided further that the Company shall not register any securities for its own account or that of any other shareholder during such 90 day period other than an Excluded Registration. 

(d)    The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to
Subsection 2.1(a) (i) during the period that is 60 days before the Company’s good faith estimate of the date of filing of, and ending on a date that is 180 days after the effective date of, a Company-initiated registration,
provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two registrations pursuant to Subsection
2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Subsection
2.1(b). The Company shall not be obligated to effect, or to take any action to 

  
 4 

 
effect, any registration pursuant to Subsection 2.1(b) (i) during the period that is 30 days before the Company’s good faith estimate of the date of filing of, and ending on a
date that is 90 days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or
(ii) if the Company has effected two registrations pursuant to Subsection 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for
purposes of this Subsection 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the
registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Subsection 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this
Subsection 2.1(d); provided, that if such withdrawal is during a period the Company has deferred taking action pursuant to Subsection 2.1(c), then the Initiating Holders may withdraw their request for registration and
such registration will not be counted as “effected” for purposes of this Subsection 2.1(d). 

2.2    Company Registration. If the Company proposes to register (including, for this purpose, a registration
effected by the Company for shareholders other than the Holders) any of its Common Shares under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration or in the IPO), the
Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within 20 days after such notice is given by the Company, the Company shall, subject to the provisions of Subsection
2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this
Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be
borne by the Company in accordance with Subsection 2.6. 
 2.3    Underwriting Requirements. 

(a)    If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable
Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The
underwriter(s) will be selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration
shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities
through such underwriting shall (together with the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of
this Subsection 2.3, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of
Registrable Securities that otherwise would be underwritten pursuant hereto, and 

  
 5 

 
the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as
nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities
held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company
or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. 
 (b)    In
connection with any offering involving an underwriting of shares of the Company’s share capital pursuant to Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting
unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by
the Company. If the total number of securities, including Registrable Securities, requested by shareholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their
reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the
Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the
Registrable Securities that are included in such offering shall be allocated on a pro rata basis among the selling Holders along with any selling Holders (as defined in the Prior Registration Rights Agreement) that have requested that Registrable
Securities (as defined in the Prior Registration Rights Agreement) be included in such underwritten offering under the Prior Registration Rights Agreement in proportion (as nearly as practicable to) the number of Registrable Securities owned by each
selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares
allocated to any Holder to the nearest 100 shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by
the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be reduced below 30% of the total number of securities included in such offering, unless such offering is the IPO,
in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other shareholder’s securities are included in such offering. For purposes of the provision in this
Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, shareholders, and Affiliates of such Holder,
or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro
rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 

  
 6 

 2.4    Obligations of the Company. Whenever required under this
Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a)    prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its
commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period
of up to 120 days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such 120 day period shall be extended for a period of time equal to the period the
Holder refrains, at the request of an underwriter of Common Shares (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such 120 day period shall be extended for up to 60 days, if necessary, to keep the registration
statement effective until all such Registrable Securities are sold; 
 (b)    prepare and file with the SEC such
amendments and supplements to such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by
such registration statement; 
 (c)    furnish to the selling Holders such numbers of copies of a prospectus, including
a preliminary prospectus, as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d)    use its commercially reasonable efforts to register and qualify the securities covered by such registration
statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do
business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e)    in the event of any underwritten public offering, enter into and perform its obligations under an underwriting
agreement, in usual and customary form, with the underwriter(s) of such offering; 
 (f)    use its commercially
reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities
issued by the Company are then listed; 
 (g)    provide a transfer agent and registrar for all Registrable Securities
registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

  
 7 

 (h)    promptly make available for inspection by the selling Holders,
any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records,
pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney,
accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i)    notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration
statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 

(j)    after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the
Company amend or supplement such registration statement or prospectus. 
 In addition, the Company shall ensure that, at all times after any
registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under
Rule 10b5-1 of the Exchange Act. 
 2.5    Furnish Information. It shall
be a condition precedent to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such
information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6    Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with
registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the
reasonable fees and disbursements, not to exceed $50,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not
be required to pay for any expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be
registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities
agree to forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material
adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall
not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Subsections 2.1(a) 

  
 8 

 
or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the
basis of the number of Registrable Securities registered on their behalf. 
 2.7    Delay of Registration. No
Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this
Section 2. 
 2.8    Indemnification. If any Registrable Securities are included in a
registration statement under this Section 2: 
 (a)    To the extent permitted by law, the
Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors, and shareholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities
Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling
Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided,
however, that the indemnity agreement contained in this Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which
consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or
on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration. 

(b)    To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless
the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any
underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent that such
Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such
selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses
are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the
consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Subsections 2.8(b) and
2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

  
 9 

 (c)    Promptly after receipt by an indemnified party under this
Subsection 2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made
against any indemnifying party under this Subsection 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so
desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together
with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified
party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice
to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure materially
prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Subsection
2.8. 
 (d)    To provide for just and equitable contribution to joint liability under the Securities Act in any
case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court
of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for
indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties
will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and
the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the
indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to
information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however,
that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no
Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such 

  
 10 

 
fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid or
payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e)    Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in
the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f)    Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public
offering, the obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall
survive the termination of this Agreement. 
 2.9    Reports Under Exchange Act. With a view to making available
to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall: 
 (a)    make and keep available adequate current public
information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b)    use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents
required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c)    furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to
the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the
IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form
S-3 (at any time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any
such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies
to use such form). 
 2.10    Limitations on Subsequent Registration Rights. From and after the date of this
Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that
would provide to such holder or 

  
 11 

 
prospective holder the right to include securities in any registration on other than either a pro rata basis with respect to the Registrable Securities or on a subordinate basis after all Holders
have had the opportunity to include in the registration and offering all shares of Registrable Securities that they wish to so include; provided that this limitation shall not apply to Registrable Securities acquired by any additional
Investor that becomes a party to this Agreement in accordance with Subsection 3.9. Notwithstanding anything herein to the contrary, the rights granted to the Holders pursuant to this Agreement are pari passu with that certain Registration
Rights Agreement, dated as of July 17, 2018, by and among the Company and the shareholders of the Company named therein (the “Prior Registration Rights Agreement”). 

2.11    “Market Stand-off” Agreement.
Each Holder hereby affirms in all respects its obligations under Sections 6.3, 6.4 and 7.2 of the Subscription Letter to which it is a party, and the terms thereof are hereby incorporated by reference in this Agreement. 

2.12    Restrictions on Transfer. 

(a)    The Preferred Shares and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the
Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except in accordance with the Articles of Association and/or the relevant Subscription Letters and upon
the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Shares and the
Registrable Securities held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. 

(b)    Each certificate, instrument, or book entry representing (i) the Preferred Shares, (ii) the Registrable
Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any share split, share dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise
permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form: 
 THE SECURITIES
REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION
AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 
 THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS
OF AN AGREEMENT BETWEEN THE COMPANY AND THE SHAREHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders
consent to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

  
 12 

 (c)    The Holder of such Restricted Securities, by acceptance of
ownership thereof, agrees to comply in all respects with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under
the Securities Act covering the proposed transaction, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the
proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall,
be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that
the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory
to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon, subject to the provisions of the Articles of Association
and/or the relevant Subscription Letters, the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company
will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder
for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided
shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Subsection 2.12(b), except that such certificate instrument, or book entry shall not be notated with such
restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act. 

2.13    Termination of Registration Rights. The right of any Holder to request registration or inclusion of
Registrable Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of: 

(a)    the closing of a Sale, as such term is defined in the Articles of Association; 

(b)    such time after consummation of the IPO as Rule 144 or another similar exemption under the Securities Act is
available for the sale of all of such Holder’s Registrable Securities without limitation during a three-month period without registration; and 

(c)    the third anniversary of the IPO. 

3.    Miscellaneous. 

3.1    Successors and Assigns. The rights under this Agreement may be assigned (but only with all related
obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; or (ii) is a Holder’s Immediate Family Member or 

  
 13 

 
trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; provided, however, that (x) the Company is, within a reasonable
time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument
delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Subsection 2.11. For the purposes of determining the number of shares of Registrable Securities held by a
transferee, the holdings of a transferee (1) that is an Affiliate or shareholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s
Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall, as a condition to the applicable
transfer, establish a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and
conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties
hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

3.2    Governing Law. This Agreement shall be governed by the internal law of the State of Delaware, without regard
to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. 

3.3    Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000,
e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.  

3.4    Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not
to be considered in construing or interpreting this Agreement. 
 3.5    Notices. 

(a)    All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be
deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the recipient’s normal business hours, and if not sent
during normal business hours, then on the recipient’s next business day; (iii) five (5) business days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) three (3) business days
after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the
respective parties at their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address,
facsimile number, or address as subsequently modified by written notice given in accordance with this Subsection 3.5. 

  
 14 

 
If notice is given to the Company, a copy shall also be sent to Fried, Frank, Harris, Shriver & Jacobson (London) LLP, 100 Bishopsgate, London EC2N 4AG, United Kingdom, Attention: Ian
Lopez, and Goodwin Procter LLP, 100 Northern Avenue, Boston, Massachusetts 02210, Attention: Edwin M. O’Connor. 

(b)    Consent to Electronic Notice. Each Investor consents to the delivery of any shareholder notice by
electronic transmission at the electronic mail address or the facsimile number provided in Schedule A. Each Investor agrees to promptly notify the Company of any change in such shareholder’s electronic mail address, and that failure to
do so shall not affect the foregoing. 
 3.6    Amendments and Waivers. Any term of this Agreement may be
amended, modified or terminated and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the Holders of
a majority of the Registrable Securities then outstanding; provided that the Company may in its sole discretion waive compliance with Subsection 2.12(c) (and the Company’s failure to object promptly in writing after notification
of a proposed assignment allegedly in violation of Subsection 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without
the consent of any other party. Notwithstanding the foregoing, this Agreement may not be amended, modified or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such
Investor, unless such amendment, modification, termination, or waiver applies to all Investors in the same fashion. Notwithstanding the foregoing, Schedule A hereto may be amended by the Company from time to time to add transferees of any
Registrable Securities in compliance with the terms of this Agreement without the consent of the other parties; and Schedule A hereto may also be amended by the Company after the date of this Agreement without the consent of the other parties
to add information regarding any additional Investor who becomes a party to this Agreement in accordance with Subsection 3.9. Any amendment, modification, termination, or waiver effected in accordance with this Subsection 3.6
shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed
as a further or continuing waiver of any such term, condition, or provision. 
 3.7    Severability. In case any
one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and
such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 

3.8    Aggregation of Shares. All shares of Registrable Securities held or acquired by Affiliates shall be
aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated Persons may apportion such rights as among themselves in any manner they deem appropriate. 

3.9    Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues
additional Preferred Shares after the date hereof, whether pursuant 

  
 15 

 
to the Subscription Letters or otherwise, any purchaser of such Preferred Shares may become a party to this Agreement by executing and delivering an additional counterpart signature page to this
Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor
has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 
 3.10    Entire
Agreement. This Agreement (including any Schedules and Exhibits hereto) together with the other agreements entered into in connection with the investment constitute the full and entire understanding and agreement among the parties with respect
to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. 

3.11    Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction
of the state and federal courts of Kent County in the State of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding
arising out of or based upon this Agreement except in the state or federal courts of Kent County in the State of Delaware, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or
proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that
the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. 

Each party will bear its own costs in respect of any disputes arising under this Agreement. The prevailing party shall be entitled to
reasonable attorney’s fees, costs, and necessary disbursements in addition to any other relief to which such party may be entitled. Each of the parties to this Agreement consents to personal jurisdiction for any equitable action sought in the
state or federal courts of Kent County in the State of Delaware. 
 3.12    Delays or Omissions. No delay or
omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting
party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach
or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

[Remainder of Page Intentionally Left Blank] 

  
 16 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	COMPANY:
	
	LumiraDx Limited
		
	By:	 	 /s/ Veronique Ameye

	Name:	 	Veronique Ameye
	Title:	 	Executive Vice President & General Counsel

  

SIGNATURE PAGE TO REGISTRATION
RIGHTS AGREEMENTEX-10.7

 Exhibit 10.7 

Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if
publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

EXECUTION VERSION 
 October 17, 2019

 LumiraDx Limited 
 3 More London Riverside 

London SEl 2AQ 
 United Kingdom 

Attention: Chief Executive Officer, Chairman and Director 
 Re:
Strategic Relationship between the Bill & Melinda Gates Foundation and LumiraDx Limited 
 Ladies and Gentlemen: 

This Amended and Restated Letter Agreement (including all appendices and attachments hereto, the “Letter Agreement”) is
entered into as of October 17, 2019 between the Bill & Melinda Gates Foundation (the “Foundation”), a Washington charitable trust that is a tax exempt private foundation, and LumiraDx Limited, an exempted company with
limited liability incorporated in the Cayman Islands under company number 314391 with its registered office at c/o Estera Trust (Cayman) Limited, PO Box 1350, Clifton House, 75 Fort Street, Grand Cayman KYl 1108, Cayman Islands (the
“Company”). This Letter Agreement amends and restates in its entirety the Letter Agreement entered into by and between the Company and the Foundation effective as of July 17, 2018 (the “Original Agreement”)
in connection with the Foundation’s program-related investment in the amount of US$19,998,823 in the Series A Convertible Preferred Shares of the Company (the “Preferred Investment”). This Letter Agreement is being entered
into in connection with the program-related investment in the form of a loan by the Foundation to the Company in the amount of US$18,000,000 (the “Loan”, and together with the Preferred Investment, the “Foundation
Investment”) in accordance with the terms of a Note Purchase Agreement dated October 17, 2019 (the “Note Purchase Agreement”) and an Unsecured Subordinated Note dated October 17, 2019 (the
“Note”). The Foundation Investment is subject to the terms and conditions of the Note Purchase Agreement, the Note, any other documents executed in connection with the Loan, and the documents executed in connection with the
Preferred Investment (collectively, and together with this Letter Agreement and any additional documents that may be executed in connection with the Foundation Investment, in each case as amended from time to time in accordance with their terms, the
“Investment Documents”). The Foundation is making the Foundation Investment to induce the Company to perform the Global Access Commitments set forth herein, and the Company acknowledges and agrees that it would not undertake such
Global Access Commitments absent the Foundation Investment. The Foundation Investment is being made in accordance with the provisions of the Investment Documents and is conditioned upon the execution and delivery of the applicable Investment
Documents by the parties thereto and the Foundation obtaining written legal opinions from tax counsel that the Foundation Investment qualifies as a program-related investment under the Code. 

 In consideration of the Foundation making the Foundation Investment on the terms and
conditions stated herein and in the other Investment Documents, and for other good and valuable consideration, the parties hereto hereby irrevocably agree as follows: 

1. Definitions. For the purposes of this Letter Agreement the following terms have the meanings indicated. 

“Accelerated Commercialization Commitment” has the meaning given in Section 3(d)(i). 

“Archetype Health System” has the meaning given in Section 3(d)(ii) 

“Additional Assay Project” has the meaning given in Section 3(c)(i). 

“Additional Projects” has the meaning given in Section 3(c)(ii). 

“Additional Accelerated Commercialization Project” has the meaning given in Section 3(c)(ii). 

“Affiliate” means, as to any person or entity, any person or entity that, directly or indirectly, controls, is controlled by or is
under common control with such person or entity at any time and for so long as that control exists, where “control” (for purposes of this definition of “Affiliate” only) means having the decision-making authority as to the person
or entity and, further, where that control will be deemed to exist where a person or entity owns more than 50% of the equity (or that lesser percentage that is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction)
entitled to vote regarding composition of the board of directors or other body entitled to direct the affairs of the person or entity. 

“Acquisition Transaction” means (a) the acquisition, directly or indirectly, after the date of this Letter Agreement, by any
person or group (within the meaning of Section 13(d)(3) of the Exchange Act) of beneficial ownership of securities of the Company possessing more than 50% of the total combined voting power of all outstanding voting securities of the Company,
(b) a merger, consolidation or other similar transaction involving the Company, except for a transaction in which the holders of the outstanding voting securities of the Company immediately prior to such merger, consolidation or other
transaction hold, in the aggregate, securities possessing more than 50% of the total combined voting power of all outstanding voting securities of the surviving entity immediately after such merger, consolidation or other transaction, or (c) an
assignment, sale, transfer or exclusive license of all or substantially all of the Company’s assets, whether by merger, stock transfer, or otherwise. 

“Challenging Market Countries” means those countries described as “Challenging Market Countries” on
Appendix A. 
 “Charitability Default” has the meaning given in Section 5(b). 

“Charitable Purpose” has the meaning given in Section 2(a). 

 “Claim” has the meaning given in Section 14. 

“Code” means the U.S. Internal Revenue Code of 1986, as amended. 

“Company” has the meaning given in the introductory paragraph. 

“Developing Countries” means those countries described as “Developing Countries” on Appendix A.

 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

“Fair Market Value” means (a) if the Foundation Securities are freely tradable, the closing price of the Foundation Securities on
the most recent day the Foundation Securities were traded on the applicable exchange prior to the closing date of the redemption or purchase or (b) if the Foundation Securities are not freely tradable, the then current fair market value as
determined by a mutually agreed upon (such agreement not to be unreasonably withheld) independent third-party appraiser. 
 “Feasibility
Grant” has the meaning given in Section 3(c)(i). 
 “Foundation” has the meaning given in the introductory
paragraph. 
 “Foundation Investment” has the meaning given in the introductory paragraph. 

“Foundation Securities” has the meaning given in Section 5(c). 

“Foundation-supported Entity” means an entity selected by the Foundation for participation in a project that receives funding,
directly or indirectly, from the Foundation, collaborates with the Foundation, or both, for the purpose of accomplishing the Foundation’s charitable objectives. 

“Funded Developments” has the meaning given in Section 3(k)(i). 

“Global Access” means that (a) knowledge gained using the Foundation’s funding is promptly and broadly disseminated and
(b) the products and technologies developed or supported with the Foundation’s funding will be made available and accessible at an affordable price to people most in need in Developing Countries. 

“Global Access Commitments” has the meaning given in Section 3. 

“Global Health License” has the meaning given in Section 3(k)(i). 

“Government Provisioned” has the meaning given in Section 3(d)(ii)(A). 

“Health Systems for Low Income People” has the meaning given in Section 3(d)(ii). 

“HIV Viral Load Assay” has the meaning given in Section 3(a). 

“HIV Viral Load Assay Development Project” has the meaning given in Section 3(a). 

“HIV Viral Load Launch Project” has the meaning given in Section 3(b)(i). 

 “Indemnitees” has the meaning given in Section 14. 

“Investment Documents” has the meaning given in the introductory paragraph. 

“Joint Steering Committee” has the meaning given in Section 3(h)(i). 

“Letter Agreement” has the meaning given in the introductory paragraph. 

“Loan” has the meaning given in the introductory paragraph. 

“Low Income People” means those individuals living at or below the World Bank poverty line for lower-middle-income countries, which,
at the time of the execution of the Letter Agreement, is US$3.20 per day. 
 “Note” has the meaning given in the introductory
paragraph. 
 “Note Purchase Agreement” has the meaning given in the introductory paragraph. 

“Original Agreement” has the meaning given in the introductory paragraph. 

“Partner with Health Systems for Low Income People” has the meaning given in Section 3(d)(iii). 

“Platform Technology” means the Company’s research, development, clinical, regulatory, manufacturing, commercialization, service
and support, and distribution capabilities in respect of point-of-care diagnostic tests, integrated assays, reagents, software and instruments, and health IT and care
solutions. This may include, but is not limited to, technology related to the dissemination and/or storage and management of diagnostic results, associated patient-related data, and quality control related data (e.g. real-time instrument
functionality and controls) within health systems. The Platform Technology includes technologies, materials, know-how, intellectual property, and intellectual property rights owned, controlled, or in licensed
by the Company or its Affiliates, whether existing at closing or later developed, owned, controlled or in licensed by the Company or its Affiliates. 

“PPP/NGO Provisioned” has the meaning given in Section 3(d)(ii)(B). 

“Preferred Investment” has the meaning given in the introductory paragraph. 

“Private Sector Provisioned” has the meaning given in Section 3(d)(ii)(C). 

“Product” means any diagnostic or other product or service developed pursuant to a Project. 

“Projects” means the HIV Viral Load Assay Development Project, HIV Viral Load Assay Launch Project, the [***] Diagnostic Instrument
Development Project, any Additional Project, and the Accelerated Commercialization Commitment. 
 “Public Market Provision” means
Government Provisioned and PPP/NGO Provisioned together. 

 “Reasonable Efforts” means the level of effort the Company would expend in the
development and commercialization of its lead commercial
 product(s). 
 “SOW” has the meaning given in Section 3(a). 

“Strategic Plan” has the meaning given in Section 3(a). 

“TPM” has the meaning given in Section 3(b)(ii). 

“TPP” has the meaning given in Section 3(a). 

“Trigger Event” has the meaning given in Section 3(k)(ii). 

“[***] Diagnostic Instrument” means a diagnostic instrument to be developed by the Company with the features set forth in the [***]
Diagnostic Instrument Target Product Profile that is low-cost, robust and appropriate for all clinical settings and intended to improve the access of people in Developing Countries to low cost point-of-care diagnostics. 
 “[***] Diagnostic Instrument Development
Plan” means the development plan for the [***] Diagnostic Instrument attached as Appendix G. 
 “[***]
Diagnostic Instrument Development Project” has the meaning given in Section 3(e). 
 “[***] Diagnostic Instrument Target
Product Profile” means the target product profile for the [***] Diagnostic Instrument attached as Appendix H. 

“[***] Joint Steering Committee” has the meaning given in Section 3(h)(ii). 

“WHO Essential Diagnostics List” means the list attached as Appendix B. 

“WHO PQ” has the meaning given in Section 3(a). 

“Withdrawal Right” has the meaning given in Section 5(c). 

2. Charitable Purpose; Use of Proceeds. 

(a) Charitable Purpose. The Foundation is making the Foundation Investment as a “program-related investment” within the
meaning of Section 4944(c) of the Code. The Foundation is committed to accelerating the development of lifesaving and low-cost drugs, therapeutics, diagnostics, and prophylactics to reduce the burden of disease in developing countries in
furtherance of its mission to help all people lead healthy, productive lives. The Foundation’s primary purpose in making the Foundation Investment is to secure Global Access to new, low-cost products and services developed through the use of
the Company’s proprietary capabilities and intellectual property, including in respect of the development, manufacturing, commercialization and distribution of (a) diagnostic tests, (b) integrated point-of-care
diagnostic platforms, and (c) connected health IT and care solutions in furtherance of the Foundation’s charitable mission (collectively, the “Charitable Purpose”). In furtherance of the Charitable Purpose, the
Foundation Investment will secure the Global Access Commitments described below. 

 (b) Use of Proceeds. 

(i) Preferred Investment. [***] of the proceeds from the Preferred Investment will be used solely to fund the HIV Viral Load Assay
Development Project and improvements in the Platform Technology in connection with the HIV Viral Load Assay Development Project in furtherance of the Charitable Purpose; provided, however, if the Joint Steering Committee at any time
determines that the Company is unlikely to meet the applicable milestones for the HIV Viral Load Assay Development Project contained in the SOW (defined below), the Company shall, at the Foundation’s election, instead apply any remaining
portion of such proceeds to an Additional Assay Project in furtherance of the Charitable Purpose. The remaining [***] of the proceeds from the Preferred Investment will be used solely to support the commercialization of the Platform Technology in
Challenging Market Countries in accordance with the Accelerated Commercialization Commitment. 
 (ii) Loan. All proceeds of the Loan
will be used solely to fund the [***] Diagnostic Instrument Development Project in furtherance of the Charitable Purpose. 
 The proceeds
from the Foundation Investment will not be required to be segregated in a separate account nor required to be used for dedicated employees or facilities. 

3. Global Access Commitments. 
 In
furtherance of the Charitable Purpose and Global Access, the Company agrees to the following (collectively “Global Access Commitments”): 

(a) HIV Viral Load Assay Development Project. The Company will diligently conduct the HIV Viral Load Assay Development Project.
“HIV Viral Load Assay Development Project” means (a) the Company’s development of an assay for HIV viral load (the “HIV Viral Load Assay”) in accordance with a mutually acceptable target
product profile (“TPP”) attached as Appendix C and scope of work (the “SOW”) attached as Appendix D through World Health Organization Pre-Qualification (“WHO PQ”) and (b) the development of a manufacturing, commercialization and distribution strategy (“Strategic Plan”) for delivery of point-of-care diagnostics within Developing Countries, including the HIV Viral Load Assay, which strategy will include the elements set forth in, and be consistent with, the
SOW for the HIV Viral Load Assay. 
 (b) HIV Viral Load Assay Launch Project. 

(i) Once the HIV Viral Load Assay has been developed as described above, the Foundation will have the right, at its discretion, to continue
providing funding (directly or through a Foundation-supported Entity) to advance the HIV Viral Load Assay through commercialization and distribution of a final product in accordance with the Strategic Plan, HIV Viral Load Assay TPP and a second
mutually acceptable SOW (the “HIV Viral Load Launch Project”). The HIV Viral Load Assay Launch Project may include applicable development, commercialization and associated activities conducted by the Company or partner(s) in
accordance with the Strategic Plan or as otherwise agreed by the Company and Foundation, if and to the extent these activities are requested by the Foundation, including seeking applicable country-level regulatory approvals. If the HIV Viral Load
Assay Launch Project is requested by the Foundation, it would be co-funded by additional funding from the Foundation or a Foundation-supported Entity pursuant to the

 
Foundation’s standard funding terms and processes. The specific level and allocation of funding responsibilities between the parties (and potentially Foundation-supported Entities) for the
HIV Viral Load Assay Launch Project will be mutually agreed in good faith in writing by the parties to fairly allocate the expected benefits between Developing Countries and developed countries. 

(ii) If the Foundation reasonably determines based on data from the HIV Viral Load Assay Development Project and/or HIV Viral Load Assay Launch
Project that the Company is unlikely to achieve prices and volumes for the HIV Viral Load Assay that are within [***] of the applicable maximum price and minimum volume commitments described in the HIV Viral Load Assay TPP and that a third-party
manufacturer (“TPM”) would likely be able to meet such price and volume commitments, the Foundation will notify the Company of such determination and provide a summary of the reasons for such determination in reasonable
detail. During the [***] period following delivery of such notice, the parties will engage in good-faith discussions regarding the Company’s ability to achieve the applicable price and volume commitments, its plan for doing so (if applicable)
and (if applicable) the reasons why a TPM may not be able to achieve such applicable price and volume commitments either. If the parties are unable to come to an agreement regarding a plan for the Company to achieve the applicable price and volume
commitments for the HIV Viral Load Assay, the Company will agree to license and transfer the necessary intellectual property and technology to such TPM (subject to such TPM entering into reasonable agreements with the Company regarding
confidentiality and use of the technology and licenses solely for the purposes contemplated herein) in order to allow the production, testing, approval, and distribution of the HIV Viral Load Assay for the Developing Countries. The Foundation will
be responsible for the reasonable costs payable for the transfer of the necessary technology to such TPM. 
 (iii) Any agreements for the HIV
Viral Load Assay Launch Project will include a proposal describing the relevant work (including specific global access commitments) and other related documents acceptable to the Foundation, and will be consistent with the HIV Viral Load Assay TPP.
The applicable funding agreements will also include a license to the HIV Viral Load Assay and related technology and intellectual property rights (including the right to sublicense or a direct grant to Foundation-supported Entities) that is
exercisable in the event of a breach of the Global Access Commitments related to the HIV Viral Load Assay Launch Project under the circumstances described below. 

(c) Additional Projects. 

(i) Additional Assay Projects. In addition to the Projects described above, if requested by the Foundation the Company will utilize the
Platform Technology to diligently conduct up to five (or two in case the Feasibility Grant as referenced below is not executed and granted) Additional Assay Projects at the Foundation’s discretion and subject to the terms below.
“Additional Assay Project” means a project proposed by the Foundation or a Foundation- supported Entity and accepted and conducted by the Company utilizing the Platform Technology to develop an assay in accordance with a
mutually agreed upon SOW and TPP, and potentially to further develop, commercialize, and distribute such assays under a similar launch project construct. It is acknowledged that the five assays covered under the “Feasibility
Grant” currently under discussion by the Parties (which include the molecular test for tuberculosis) would, if funding agreements for such Feasibility Grant are executed and the applicable work contemplated thereby is conducted,
exhaust all five Additional Assay Projects. 

 (ii) Additional Accelerated Commercialization Project. In addition, if requested by
the Foundation, subject to the Terms of Additional Projects outlined below, the Company will diligently conduct the Additional Accelerated Commercialization Project. “Additional Accelerated Commercialization Project” means a
project to accelerate commercialization of the Company’s products in a minimum of three countries among [***] in accordance with a mutually agreed SOW. The Additional Accelerated Commercialization Project and Additional Assay Projects are
referred to collectively as “Additional Projects”. 
 (iii) Terms of Additional Projects. Each Additional Project
will be funded and conducted pursuant to the Foundation’s standard funding terms and processes, which would include a proposal prepared in good faith by the Company (which will be submitted within [***] after the Foundation’s initial
request to the Company) describing the relevant work to be conducted by the Company and other related documents acceptable to the Foundation. If the Foundation requests that the Company continue development and commercialization of an assay
developed through an Additional Assay Project, the Company will consider in good faith and the parties will negotiate in good faith the terms of the applicable grant documents for such work. To the extent the parties agree to continue support of an
Additional Project, the specific level and allocation of additional funding responsibilities for such Additional Project will be mutually agreed in good faith in writing by the parties based on a fair allocation of the expected benefits between
Developing Countries and developed countries. 
 (d) Accelerated Commercialization Commitment. 

(i) The Company will diligently conduct the Accelerated Commercialization Commitment as further described below. “Accelerated
Commercialization Commitment” means (A) the Company’s commitment to Partner with Health Systems for Low Income People and (B) the Company’s commitment to Align with Essential Diagnostic List Market Coordination.

 (ii) The health systems serving Low Income People in Challenging Market Countries are heterogenous and very different from those in the US
and Europe. Often, they include the three archetype health delivery systems listed below. Each of these three health delivery systems operating in a Challenging Market Country is a different “Archetype Health System” and
collectively these three Archetype Health Systems are defined as “Health Systems for Low Income People.” 
 (A)
“Government Provisioned” means government healthcare providers that are publicly owned and operated including community healthcare workers, primary and community health centers, district and regional health centers, government-run pharmacies and diagnostic labs, and government-supported ambulance services. 
 (B)
“PPP/NGO Provisioned” means public-private-partnerships or non-government organization providers of publicly or philanthropically owned and publicly or privately operated healthcare
professionals operating community outreach programs (e.g., Médecins Sans Frontières), or healthcare services in partnership with governments (e.g. public-private-partnership clinics for outpatient care). 

 (C) “Private Sector Provisioned” means providers that are privately
owned and operated below the tertiary care level, including individual or consolidated chains of primary care clinics, pharmacies, ambulances, and home-based care services. 

(iii) The Company’s commitment to “Partner with Health Systems for Low Income People” consists of the following:

 (A) By [***], the Company will have [***]; 

(B) By [***], the Company will have [***]; 

(C) During the [***], Health Systems for Low Income People will have [***]; 

(D) During the [***], Health Systems for Low Income People will have [***]; 

(E) During the [***], Health Systems for Low Income People will have [***]; 

(F) During the [***], Health Systems for Low Income People will have [***]; and 

(G) During the [***], Health Systems for Low Income People will [***]. 

(iv) The Company’s commitment to “Align with Essential Diagnostic List Market Coordination” consists of good-faith
efforts to achieve the following: 
 (A) The Company will [***]; 

(B) The Company will [***]; and 

(C) The Company will [***]. 
 (v)
The Foundation understands that the achievement of the Accelerated Commercialization Commitments is dependent on the cooperation and/or purchase commitments of third-parties and the Archetype Health System operators. In the event the Company is
concerned that a lack of cooperation or commitment from Archetype Health System operators will make it impossible to achieve one or more of the Accelerated Commercialization Commitments, the Company may request the Foundation to assist with
discussions with such Archetype Health System operators and/or make other good-faith efforts to support the Company’s commercialization efforts. Where Accelerated Commercialization Commitments require changes or alterations (which are not
foreseen under the Company business plans) to the Platform Technology, instrument or assays to adjust these for resource-poor settings or projects or specific delivery or service models, extensions to timelines may be required. In the event of such

 
occurrence, the parties will discuss in good faith and (A) the Accelerated Commercialization Commitments may be modified; or (B) the Foundation may provide additional funding for such
project to achieve the Accelerated Commercialization Commitments, each of (A) and (B) at the sole discretion of the Foundation. 
 (e)
[***] Diagnostic Instrument Development Project. The Company will utilize the Platform Technology to diligently develop the [***] Diagnostic Instrument and assays thereon through commercialization no later than [***] (“[***]
Diagnostic Instrument Development Project”). The [***] Diagnostic Instrument will be developed in accordance with the [***] Diagnostic Instrument Development Plan. As part of the [***] Diagnostic Instrument Development Project, the Company
will use Reasonable Efforts to achieve the COGS goals set forth in the [***] Target Product Profile. The Company will provide the Foundation with documentation in the form of copies of invoices, relevant regulatory filings and/or clearances,
certified cost of goods statements and other documents that may be requested by the Foundation to demonstrate COGS of the [***] Diagnostic Instrument. 

(f) Receipt and Continuation of Licenses. The Foundation Investment will be conditioned on the Company’s receipt and continuation
of all necessary licenses and rights with respect to the Platform Technology needed to perform the Global Access Commitments. 
 (g)
Pricing and Volume Commitments. 
 (i) Products Developed Pursuant to the HIV Viral Load Assay Development Project, HIV Viral Load
Assay Launch Project, and Any Additional Assay Project. The Company agrees to make available to Low Income People in Developing Countries any Products developed and commercialized pursuant to the HIV Viral Load Assay Development Project, HIV Viral
Load Assay Launch Project, and any Additional Assay Project (a) at or below the price set forth in the applicable TPP and (b) in quantities meeting or exceeding those set forth in the applicable SOW (or other applicable global
access agreements between the Foundation and the Company). Additionally, other Products developed and distributed by the Company for Public Market Provision in the Challenging Market Countries will be commercialized consistent with the affordability
and availability intent of Global Access. In the event that the Foundation notifies the Company of the Foundation’s concerns that the affordability and availability intent of Global Access is being violated in a specific Challenging Market
Country, the parties agree to work together in good faith to rectify the concern to the satisfaction of the Foundation. These commitments do not apply to sales of Products used outside of the Developing Countries. 

(ii) [***] Diagnostic Instrument. The Company will make the [***] Diagnostic Instrument available to serve Low Income People in
Challenging Market Countries at an affordable price that is no greater than the maximum price and in at least the minimum volumes set forth in the [***] Target Product Profile. These commitments do not apply to sales of products used outside of
Challenging Market Countries or not targeting Low Income People. 

 (h) Joint Steering Committees. 

(i) Joint Steering Committee. The parties will each designate two individuals who are subject matter experts to be part of a joint
steering committee (the “Joint Steering Committee”) that provides a forum for discussion of the progress of the (a) Platform Technology and (b) the Projects (other than the [***] Diagnostic Instrument
Project). Certain key decisions of the Joint Steering Committee related to advancing to the next phase of development (as outlined in the SOW) will require the affirmative vote of the individuals designated by the Foundation. The Joint Steering
Committee will meet at least once quarterly via teleconference and at least once annually in-person. With the agreement of both parties and subject to the execution of appropriate confidentiality agreements,
third-parties may be invited from time to time to participate in certain Joint Steering Committee discussions, it being understood that the Company may object if competitive sensitive information would be released to one of its competitors. 

(ii) [***] Joint Steering Committee. In addition to the Joint Steering Committee described above, the parties will (a) each
designate one individual and (b) mutually designate one additional individual who is a subject matter expert to be part of a joint steering committee (the “[***] Joint Steering Committee”) that would provide a forum for
discussion of the progress of the [***] Diagnostic Instrument Development Project and channels and conditions to provide access to the [***] Diagnostic Instruments. Decisions of the [***] Joint Steering Committee, including in respect of
determinations regarding compliance with the pricing and volume commitments described in Section 3(g)(ii) above, will be made by majority vote, provided that certain key decisions of the [***] Joint Steering Committee related to
advancing to the next phase of development as outlined in the [***] Diagnostic Instrument Development Plan would require the approval of the individual designated by the Foundation, it being acknowledged that if the Foundation does not wish to
proceed to a next phase, the Company shall be entitled to continue to proceed at its own cost. The [***] Joint Steering Committee would meet at least once quarterly via teleconference and at least once annually
in-person. With the agreement of both parties and subject to the execution of appropriate confidentiality agreements, third parties may be invited from time to time to participate in certain [***] Joint
Steering Committee discussions, it being understood that the Company may object if competitive sensitive information would be released to one of its competitors. 

(iii) Additional Communications. In addition, if requested by the Foundation, members of the Company’s technical team will meet
with Foundation programmatic representatives at least once quarterly via teleconference or onsite visits at Company facilities to provide an update on any of the Projects, with such updates to provide a level of detail sufficient to assess the
status of such Projects against the applicable scopes of work and TPPs (as applicable). 
 (i) Publication; Access to Data and
Information. The Company will (in addition to the publication requirements of any other agreements with the Foundation): 
 (i) publish
the results and information developed in connection with each Project within a reasonable period of time after such information or results are obtained, subject to reasonable delays or limitations on content of such publications that are necessary
to protect intellectual property and trade secrets covering the Platform Technology itself. All publications must be made in accordance with “open access” terms and conditions consistent with the Foundation’s Open Access Policy
(available at: http://www.gatesfoundation.org/How-We- Work/General-Information/Open-Access-Policy), which may be modified from time to time; 

 (ii) promptly provide to the Foundation from time to time, upon the Foundation’s
request, access to data and information regarding the Projects, the reasonably contemplated use of the Platform Technology for such Projects, and the considerations made by the Company with respect to accessibility, affordability and cost
effectiveness; and 
 (iii) promptly provide to the Foundation from time to time, upon the Foundation’s request, rights to share such
data and information regarding the Projects, and the reasonably contemplated use of the Platform Technology for the Projects, subject to the reasonable need to protect confidential information and to avoid untimely public disclosures that may bar
access to patent protection or public disclosures that may undermine trade secret protection. 
 (j) No Inconsistent Rights. The
Company will not grant to a third-party any rights or enter into any arrangements or agreements that would limit or restrict the Foundation’s rights to the Global Access Commitments. 

(k) Global Health License. 

(i) Global Health License. In connection with and relating to the Projects (other than any Additional Project that has not yet resulted
in a product that was funded by the Foundation and sold in a Challenging Market Country), the Company hereby grants the Foundation and/or Foundation-supported Entities a worldwide, non-exclusive, non-terminable, perpetual, royalty-free license (with the right to sublicense) to the products, technologies, materials, processes, and other intellectual property and intellectual property rights developed using
funds from the Foundation or a Foundation-supported Entity or developed in connection with the Company’s conduct of such Projects (the “Funded Developments”) and the background intellectual property of the Company that
covers or is used in the Platform Technology and/or such Projects to use, reproduce, modify, make, distribute, sell, offer-for-sale, import, and otherwise dispose of
diagnostic products and services directed at pathogens or diseases that disproportionately affect people in Developing Countries in a manner consistent with the Foundation’s Charitable Purpose (“Global Health License”). The
Global Health License is a presently granted license. The Foundation will not exercise the Global Health License except in the event of a Trigger Event and Foundation’s rights upon exercise of such Global Health License will extend only to the
Product or Project from which the Trigger Event arises and only in furtherance of the Foundation’s Charitable Purpose. In the event of a Trigger Event that applies only to a particular Product or Project, the Foundation will have the right to
exercise the Global Health License (and the Company will have the obligation to take the further actions described in the following subsection (k)) only for such Product or Project. For avoidance of doubt, Additional Projects that result in
products funded by the Foundation and sold in one or more Challenging Market Countries shall be subject to the Global Health License which shall be exercisable only in the event of a Trigger Event. 

(ii) Trigger Events. The Foundation will not exercise its rights under the Global Health License (including its sublicensing rights)
unless at least one of the following occurs (each, a “Trigger Event”): 
 (A) a Charitability Default that remains uncured
for [***] following written notice by either party of such Charitability Default; or 

 (B) the Company (1) institutes any bankruptcy, insolvency, appointment of a receiver
and/or trustee or reorganization (in either case for the release of financially distressed debtors), general assignment for the benefit of creditors, winding-up, dissolution, liquidation or similar proceeding
relating to it under the laws of any jurisdiction or any such proceeding is instituted against the Company which remains undismissed or unstayed for a period of [***] or (2) ceases to conduct business in the ordinary course or is
determined to no longer be a going concern. 
 If either the Foundation or the Company becomes aware of a Trigger Event, it will promptly
notify the other party in writing of the occurrence of such Trigger Event. 
 (l) Cooperation; Technology Transfer. In connection with
the exercise of any license hereunder the Company will take further actions, including technology transfer (subject to appropriate confidentiality obligations), as would be commercially reasonable industry practice at the time with respect to
providing a biotechnology license to a third party, to accommodate that the Foundation, the Foundation’s sublicensees, and/or the relevant Foundation-supported Entity can effectively exercise the applicable Global Health License and use the
related technology and manufacture the relevant Products if a Trigger Event occurs (including the right to reference regulatory filings related to the applicable Products), in each case solely as permitted under the Global Health License.
Notwithstanding the foregoing, the technology transfer obligations described above will not apply with respect to the Company’s confidential manufacturing processes or technologies related to its Delta ModTech manufacturing line(s) so long as,
if requested by the Foundation, the Company enters into and performs its obligations under a supply agreement with the Foundation or a Foundation-supported Entity for the manufacture of the applicable funded product at a price that does not exceed
the Company’s cost of goods (Ex-Works) sold plus [***] and subject to other terms that are reasonably acceptable to the parties. 

(m) Intellectual Property Rights. The Company represents and covenants that the Company has and will continue to have all necessary
rights to the Platform Technology (including all rights in any patents, copyrights, trademarks, trade secrets, data, confidential information, know-how, and other intellectual property or proprietary right)
needed to perform the Global Access Commitments and grant the licenses hereunder. 
 (n) Duration of Global Access Commitments. The
Global Access Commitments will be ongoing and will continue for as long as the Foundation exists, except that (i) the Company’s obligation to accept Additional Assay Projects (in accordance with the terms above) will terminate seven years
following the closing of the initial Foundation Investment (such [***] period will be extended to accommodate initiation of any Additional Assay Projects that may be under discussion by the parties at the end of such period) and (ii) the
price and volume commitments set forth in Section 3(g)(ii) in respect of the [***] Diagnostic Instrument will expire [***] following the first commercial launch of the [***] Diagnostic Instrument in a Challenging Market Country. 

 4. Survival of Global Access Commitments. 

In the event of (i) an Acquisition Transaction, or (ii) the sale, exclusive license, or other transfer of the Platform Technology
owned or controlled by the Company or the Funded Developments, the Global Access Commitments will survive and be assumed in full by the purchaser, transferee, licensee, or acquirer and the Company will take all action necessary to ensure such
assumption. The Foundation will have the right to review the provisions of the written agreement with such third-party that relate to the assumption of the Global Access Commitments to confirm that the Global Access Commitments will survive and be
assumed by the third-party and will continue to be directly enforceable by the Foundation. For clarity, notwithstanding anything to the contrary in this Letter Agreement, the Foundation’s rights hereunder that exist on the date of the
Acquisition Transaction or sale, exclusive license, or other transfer of the Platform Technology or the Funded Developments will not be terminated by such transaction. 

In addition, at the earlier to occur of (a) the agreement by the Company with a third party on the key terms of an Acquisition
Transaction or (b) [***] prior to the closing of an Acquisition Transaction, the Company will provide the Foundation with written notice of the proposed Acquisition Transaction. The Company will also work in good faith with the Foundation and the
proposed acquirer to develop and agree to (prior to the closing of such Acquisition Transaction) a written plan that is acceptable to the Foundation that provides adequate assurances of the continued performance and timely transition of the Global
Access Commitments. Among other things, the plan will describe the resource commitments and timeline to support the transition and will provide that the personnel responsible for performance of the Global Access Commitments will have a level of
knowledge and experience that is appropriate for such performance. Upon approval of the plan by the Foundation, the plan will become part of the Global Access Commitments and will be binding on the Company and acquirer. 

5. Withdrawal Right. 
 (a) The
Withdrawal Right described and defined in this Section 5 will be triggered only as a result of a Charitability Default. 
 (b) A
“Charitability Default” means that the Company (i) is in material breach of any of the Global Access Commitments, including the failure to conduct the Projects as described herein, other than for reasons of technical or
scientific failure not within the control of the Company and not known to the Company at or before closing of each Foundation Investment, (ii) fails to comply with the restrictions in Sections 2 and 9 of this Letter Agreement on the
use of proceeds from the Foundation Investment, or (iii) fails to comply with the other related U.S. legal obligations set forth in this Letter Agreement, including the requirements set forth in Sections 6, 9, 11, and 12.
Each party agrees to promptly notify the other party in writing if it becomes aware of a Charitability Default and the Company will thereafter promptly provide to the Foundation a proposed strategy to remedy the Charitability Default.
Notwithstanding the foregoing, the Foundation will not lose any rights or remedies solely as a result of a failure to notify the Company after it becomes aware of a Charitability Default. 

(c) If the Company fails to cure the Charitability Default within [***] of the Foundation’s written notice of such Charitability Default,
and if the Foundation holds any securities of the Company, including securities issued in respect of or upon conversion or exercise of such securities (collectively, the “Foundation Securities”) or any loans from the
Foundation are outstanding, in each case issued or extended in connection with the Foundation Investment, the Company will have the obligation, if requested by the Foundation, to (i) redeem all of the Foundation Securities or locate a
third-party that will purchase the Foundation Securities and (ii) to 

 
repay the entire unpaid principal and accrued and unpaid interest on such loans without presentment, demand, protest or notice of any kind, all of which are expressly waived ((i) and (ii), the
“Withdrawal Right”). If the Company is unable to redeem all of the Foundation Securities, and no third party purchases the Foundation Securities, then the Company will use its best efforts to effect the Withdrawal Right, consistent
with the Code and applicable law, as soon as practicable. During any period when the Company is unable to exercise its obligations with respect to the Withdrawal Right, the Company will not pay dividends on any of its capital stock, redeem the
capital stock of any other stockholder of the Company (excluding repurchases of stock from former employees, officers, directors, consultants or other persons who performed services for the Company or any subsidiary in connection with the cessation
of such employment or service at the lower of the original purchase price or the then-current fair market value thereof) or otherwise make any other distribution to any other stockholder of the Company (other than shares of common stock or stock
options issued to employees or directors of, or consultants or advisors to, the Company or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board of Directors of the Company). The Company’s obligations in
connection with the Withdrawal Right will be subordinate to the Company’s repayment obligations with respect to the Senior Indebtedness (as defined in the Note). 

(d) For redemption or purchase by the Company or a third-party pursuant to Section 5(c), the Foundation Securities will be valued at the
greater of (i) the original purchase price attributable to such shares plus a [***] per annum compounding interest rate calculated from the date of issuance of the Foundation Securities through the date of redemption or purchase or
(ii) Fair Market Value. 
 (e) Notwithstanding any exercise of the Withdrawal Right by the Foundation, the Foundation’s
rights under the Global Access Commitments will survive. 
 6. Required Reporting; Audit Rights. 

(a) In addition to reports required to be delivered to the Foundation under the Investment Documents, the Company will furnish, or cause to be
furnished, to the Foundation the following reports and certifications: 
 (i) within [***] after the end of each of the Company’s fiscal
years during which the Foundation owns any securities in the Company, a certificate from the Company signed by an officer of the Company and substantially in the form attached to this Letter Agreement as Appendix E,
certifying that the requirements of the Foundation Investment set forth in this Letter Agreement were met during the immediately preceding fiscal year, describing the use of the proceeds of the Foundation Investment and evaluating the Company’s
progress toward achieving the Global Access Commitments; 
 (ii) within [***] after the end of the Company’s fiscal year during which
the Foundation ceases to own any securities in the Company, a certificate from the Company signed by an officer of the Company and substantially in the form attached to this Letter Agreement as Appendix F, certifying that
the requirements of the Foundation Investment set forth in this Letter Agreement were met during the term of the Foundation Investment, describing the use of the proceeds of the Foundation Investment and evaluating the Company’s progress toward
achieving the Global Access Commitments; 

 (iii) any other information respecting the operations, activities and financial condition of
the Company as the Foundation may from time to time reasonably request to discharge any expenditure responsibility, within the meaning of Sections 4945(d)(4) and 4945(h) of the Code, of the Foundation with respect to the Foundation Investment,
and to otherwise monitor the charitable benefits intended to be served by the Foundation Investment. The Foundation will reimburse the Company for any reasonable third-party expenses incurred by the Company in order to prepare any information the
Company is required to prepare solely as a result of this Section 6(a)(iii); and 
 (iv) full and complete financial reports of
the type ordinarily required by commercial investors under similar circumstances to the extent required pursuant to Treasury Regulation 53.4945-5(b)(4). 

(b) At the Foundation’s reasonable request, the Company will provide the Foundation with a summary of scientific data and progress to date
on all Projects and any Platform Technology related to the foregoing, and the considerations made by the Company with respect to accessibility, affordability and cost-effectiveness of the applicable Products for people and payors in Developing
Countries, in addition to the information that may be required under any grant agreements or other funding agreements. 
 (c) Without
limiting the foregoing, at the Foundation’s request, the Company will permit the Foundation or its representatives to inspect (at a reasonable time and location) the scientific records of the Company relating to each Project with due regard to
the reasonable need to protect trade secrets covering the Platform Technology. 
 (d) The Company will maintain books and records adequate to
provide information ordinarily required by commercial investors under similar circumstances, including accounting records and copies of any reports submitted to the Foundation related to each Project. The Company will retain such books, records, and
reports for four years after the Foundation ceases to hold Company securities and will make such books, records, and reports available to the Foundation at reasonable times to enable the Foundation to monitor and evaluate how the Foundation’s
funds have been used. 
 (e) The Company will permit employees or agents of the Foundation at any reasonable time and upon reasonable prior
notice, during normal business hours, to examine or audit the Company’s books and accounts of record and to make copies and memoranda of the same, in each case at the Foundation’s expense to audit the Company’s compliance with the use
of the Foundation Investment and the Global Access Commitments. If the Company maintains any records (including computer-generated records and computer software programs for the generation of such records) in the possession of a third party, the
Company, upon request of the Foundation, will notify such party to permit the Foundation free access to such records at all reasonable times and to provide the Foundation with copies of any records it may reasonably request in connection with such
audit, request or inquiry, all at the Foundation’s expense. 

 7. Board Observer. 

In addition to the Foundation’s right to appoint a director to the Company’s Board of Directors (as set forth in the other Investment
Documents), as long as the Foundation or an Affiliate thereof owns any Foundation Securities, the Foundation shall be entitled to designate one person to attend all meetings of the Company’s Board of Directors and committees thereof in a
nonvoting observer capacity and the Company shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors;
provided that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the
attorney-client privilege between the Company and its counsel or result in a potential conflict of interest on the part of the Foundation. 
 8.
Assignment. 
 Notwithstanding anything in this Letter Agreement or any Investment Document to the contrary, the Foundation will
have the right to assign this Letter Agreement or transfer the Foundation Securities to (a) any successor charitable organization of the Foundation from time to time that is a tax exempt organization as described in Section 50l(c)(3) of
the Code, or (b) any tax exempt organization as described in Section 50l(c)(3) of the Code controlled by one or more trustees of the Foundation. The Foundation will notify the Company of any such assignment, including the identity of the
assignee, in a timely manner. For the avoidance of doubt, if the Foundation transfers the Foundation Securities as permitted by this Section 8, the Foundation may assign to any such transferee all of its rights attached to such Foundation
Securities, including the Withdrawal Right. 
 9. Prohibited Uses. 

The Company will not expend any proceeds of the Foundation Investment to carry on propaganda or otherwise to attempt to influence legislation,
to influence the outcome of any specific public election or to carry on, directly or indirectly, any voter registration drive, or to participate or intervene in any political campaign on behalf of or in opposition to any candidate for public office
within the meaning of Section 4945(d) of the Code. The proceeds of the Foundation Investment will not (a) be earmarked to be used for any activity, appearance or communication associated with the activities described in the foregoing
sentence, nor (b) be intended for the direct benefit, and will not benefit, any person having a personal or private interest in the Foundation, including descendants of the founders of the Foundation, or persons related to or controlled by,
directly or indirectly, such private interests. 
 For the avoidance of doubt, the Company will not use the funds received from the
Foundation to pay a dividend or redeem shares. 
 10. Disqualified Person. 

Neither the Company nor (to the best knowledge of the Company) any stockholder of the Company is a “disqualified person” with respect
to the Foundation (as the term “disqualified person” is defined in Section 4946(a) of the Code). The Foundation does not, and one or more disqualified persons with respect to the Foundation do not, directly or indirectly, control the
Company. 

 11. Anti-Terrorism. 

The Company will not use any portion of the Foundation Investment, directly or indirectly, in support of activities (a) prohibited by U.S.
laws related to combatting terrorism; (b) with persons on the List of Specially Designated Nationals (www.treasury.gov/sdn) or entities owned or controlled by such persons; or (c) with countries or territories against which the U.S.
maintains comprehensive sanctions (currently, Cuba, Iran, (North) Sudan, Syria, North Korea, and the Crimean Region of Ukraine), unless such activities are fully authorized by the U.S. government under applicable law and specifically approved by the
Foundation in its sole discretion. 
 12. Anti-Corruption and Anti-Bribery. 

The Company will not offer or provide money, gifts, or any other things of value directly or indirectly to anyone in order to improperly
influence any act or decision relating to the Foundation or any activities contemplated by this Letter Agreement or the Company’s organizational documents (e.g., certificate of incorporation or articles of association), including by assisting
any party to secure an unlawful advantage. Training and information on compliance with these requirements are available at www.leamfoundationlaw.org. 

13. Public Reports; Use of Name. 

The Foundation may include information on this investment in its periodic public reports and may make the investment public at any time on its
web page and as part of press releases, public reports, speeches, newsletters and other public document, and to the extent required by applicable law or regulation. Any announcement of the Foundation Investment by any other party, including the
Company, its representatives, directors, stockholders and agents, or any investor, will require the Foundation’s prior written approval. Such parties will also obtain the Foundation’s prior written approval for any other use of the
Foundation’s name or logo in any respect; provided, however, that the Company may use the Foundation’s name for any uses that have been pre-approved in writing by the Foundation.
Notwithstanding the foregoing, the Foundation’s name and logo will not be used by any party in any manner to market, sell or otherwise promote the Company, its products, services and/or business. 

14. Indemnification. 
 The Company
will indemnify, hold harmless, and defend the Foundation and its co-chairs, trustees, directors, officers, employees, agents, and representatives (collectively, the “Indemnitees”) from
and against any and all third party causes of action, claims, suits, legal proceedings, judgments, settlements, damages, penalties, losses, liabilities and costs (including reasonable attorneys’ fees and costs) (each a
“Claim”) finally awarded to such-third party by a court of competent jurisdiction against any of the Indemnitees or agreed to as part of a monetary settlement of the Claim and arising out of or relating to: (a) bodily
injury, death or property damage caused by the activities or omissions of the Company, including any development or commercialization or distribution activities carried out by the Company (including any failure to comply with applicable laws,
regulations or rules in connection therewith), or by any product; or 

 
(b) any Claim that the Platform Technology, any Funded Development or any product infringes upon a patent, proprietary, or other intellectual property right of a third-party. The Foundation will
give the Company prompt written notice of any Claim subject to indemnification; provided, that the Foundation’s failure to promptly notify the Company will not affect the Company’s indemnification obligations except to the extent
that the Foundation’s delay prejudices the Company’s ability to defend the Claim. The Company will have sole control over the defense and settlement of each and every Claim, with counsel of its own choosing which is reasonably acceptable
to the Foundation; provided, that the Company conducts the defense actively and diligently at the sole cost and expense of the Company and provided further that the Company will not enter into any settlement that adversely affects any
Indemnitee without the applicable Indemnitee’s prior written consent, such consent not to be unreasonably withheld, conditioned or delayed. The Foundation will provide the Company, upon request, with reasonable cooperation in connection with
the defense and settlement of the Claim. Subject to the Company’s rights above to control the defense and settlement of Claims, the Foundation and any Indemnitee may, at its own expense, employ separate counsel to monitor and participate in the
defense of any Claim under this Section 14. 
 The parties will not be liable to each other for any indirect, incidental,
consequential, or special damages (including lost revenues, lost savings, or lost profits suffered by such other party) suffered by such other party arising under or in connection with this Letter Agreement, regardless of the form of action, whether
in contract or tort, including negligence of any kind, whether active or passive, and regardless of whether the party knew of the possibility that such damages could result; provided, that to the extent an Indemnitee is entitled to be
indemnified hereunder for Claims of third parties and such third party has been awarded indirect, incidental, consequential, reliance, or special damages (including lost revenues, lost savings, or lost profits), the Company’s indemnification
obligations to the Indemnitee will extend to and include such third party’s indirect, incidental, consequential, reliance, or special damages (including lost revenues, lost savings, or lost profits). The parties further agree that under no
circumstances will any party be liable to the other party (or to any Indemnitee) more than once for the same losses arising under or in connection with this Letter Agreement. 

15. Insurance. 
 The Company agrees
to maintain insurance coverage sufficient to cover the activities, risks, and potential omissions in respect of the Projects in accordance with generally-accepted industry standards and as required by law. The Company will ensure all subcontractors
maintain insurance coverage consistent with this paragraph. 
 16. Compliance with Laws and Requirements; Responsibility. 

The Company will comply with all applicable laws and regulations, including intellectual property laws. The Company will conduct, control,
manage, and monitor the Projects in compliance with all applicable ethical, legal, regulatory, and safety requirements, including applicable international, national, local, and institutional standards. The Company will obtain and maintain all
necessary approvals, consents, and reviews before conducting the applicable activity. If a Project involves: 

 (a) any protected information (including personally identifiable, protected health, or third
party confidential), the Company will not disclose this information to the Foundation without obtaining the Foundation’s prior written approval and all necessary consents to disclose such information; 

(b) children or vulnerable subjects, the Company will obtain any necessary consents and approvals unique to these subjects; or 

(c) any trial involving human subjects, the Company will adhere to current Good Clinical Practice as defined by the International Council on
Harmonisation (ICH) E-6 Standards (or local regulations if more stringent) and will obtain applicable trial insurance. 

The Company will be solely responsible and liable for all activities related to the conduct of the Projects. For avoidance of doubt, as between the Foundation
and the Company, the Company will have responsibility for all clinical trials. Any activities by the Foundation in reviewing documents and providing input or funding do not modify the Company’s responsibility, including responsibility for
determining and complying with the provisions of this Section 16. 
 17. Entire Agreement; Modification. 

The terms and conditions set forth in this Letter Agreement are in addition to the provisions stated in the other Investment Documents and the
terms and conditions of this Letter Agreement will prevail over any inconsistent provision in any other Investment Document. No change, modification or waiver of any term or condition of this Letter Agreement will be valid unless it is in writing,
it is signed by the party to be bound, and it expressly refers to this Letter Agreement. 
 18. Authority; Governing Law. 

Each of the signatories below covenants, represents and warrants that he, she or it had all authority necessary to execute this Letter
Agreement and that, on execution, this Letter Agreement will be fully binding and enforceable in accordance with its terms, and that no other consents or approvals of any other person or third parties are required or necessary for this Letter
Agreement to be so binding. This Letter Agreement will be governed by the laws of England and Wales, excluding its conflicts of laws provisions. 
 19.
Counterparts. 
 This Letter Agreement may be executed in one or more counterparts, each of which will be deemed an original, but
all of which will be deemed to be and constitute one and the same instrument. 
 20. Construction. 

Section headings are not to be considered part of this Letter Agreement, are included solely for convenience, are not intended to be full or
accurate descriptions of the content thereof, and will not effect the construction of this Letter Agreement. The words “include,” “includes” and “including” will be considered to be followed by the words “without
limitation”. 
 [Signature Page Follows] 

 The parties have caused this Letter Agreement to be executed as of the date first set forth above. 

 

									
	LumiraDx Limited	 		  	Bill & Melinda Gates Foundation
					
	By:	 	 /s/ David Scott
	 	        	  	By:	  	 /s/ Carolyn Ainslie

	Name: David Scott	 		  	Name: Carolyn Ainslie
	Title: Director	 		  	Title: Chief Financial Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]